Mosaic Financial Group LLC Takes $913,000 Position in AstraZeneca PLC $AZNCF

Mosaic Financial Group LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,205 shares of the company’s stock, valued at approximately $913,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of AZNCF. Vaughan David Investments LLC IL bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $88,367,000. Azimuth Capital Investment Management LLC bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $20,440,000. L & S Advisors Inc bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $14,863,000. Hendley & Co. Inc. bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $11,373,000. Finally, Burling Wealth Partners LLC bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $4,532,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Performance

OTCMKTS AZNCF opened at $187.10 on Monday. AstraZeneca PLC has a 52 week low of $122.26 and a 52 week high of $195.00. The business has a 50 day moving average price of $187.10 and a 200-day moving average price of $186.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.